Technical Analysis for CRDF - Cardiff Oncology, Inc.

Grade Last Price % Change Price Change
B 3.21 2.72% 0.09
CRDF closed up 2.72 percent on Friday, November 1, 2024, on 1.21 times normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Earnings Movers Other 0.00%
Inside Day Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
Volume Surge Other 2.72%
Upper Bollinger Band Walk Strength 2.72%
Earnings Movers Other 2.72%
Outside Day Range Expansion 2.72%
Gapped Up Strength 2.72%
Upper Bollinger Band Touch Strength 2.72%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 19 hours ago
2x Volume Pace about 23 hours ago
1.5x Volume Pace about 23 hours ago
3x Volume Pace about 23 hours ago
Up 5% about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cardiff Oncology, Inc. Description

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Cancer Treatment Oncology Phosphates Acute Myeloid Leukemia Chemotherapy Lymphoma Prostate Cancer Antineoplastic Drugs Colorectal Cancer Leukemia Targeted Therapy Advanced Solid Tumors Solid Tumor Cancers Adenosine Metastatic Colorectal Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Nektar Therapeutics

Is CRDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.42
52 Week Low 0.94
Average Volume 564,287
200-Day Moving Average 2.99
50-Day Moving Average 2.61
20-Day Moving Average 2.82
10-Day Moving Average 2.96
Average True Range 0.22
RSI (14) 69.23
ADX 37.03
+DI 30.40
-DI 7.11
Chandelier Exit (Long, 3 ATRs) 2.75
Chandelier Exit (Short, 3 ATRs) 3.11
Upper Bollinger Bands 3.21
Lower Bollinger Band 2.43
Percent B (%b) 0.99
BandWidth 27.85
MACD Line 0.15
MACD Signal Line 0.11
MACD Histogram 0.0367
Fundamentals Value
Market Cap 143.19 Million
Num Shares 44.7 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -3.48
Price-to-Sales 174.60
Price-to-Book 1.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.57
Resistance 3 (R3) 3.58 3.47 3.51
Resistance 2 (R2) 3.47 3.38 3.46 3.48
Resistance 1 (R1) 3.34 3.32 3.40 3.33 3.46
Pivot Point 3.23 3.23 3.26 3.22 3.23
Support 1 (S1) 3.10 3.14 3.16 3.09 2.95
Support 2 (S2) 2.99 3.08 2.98 2.93
Support 3 (S3) 2.86 2.99 2.91
Support 4 (S4) 2.85